 SOUTH SAN FRANCISCO, Calif., Oct. 05, 2021 GLOBE NEWSWIRE -- Harpoon Therapeutics, Inc. NASDAQ: HARP, a clinical-stage immunotherapy company developing a novel class of T cell engagers, today announced that an abstract with preclinical data of its TriTAC-XR T cell engager platform has been accepted for poster presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer SITC. The meeting will be held virtually and in person in Washington, D.C. from November 10-14, 2021. 